Peer Review History

Original SubmissionJuly 14, 2022
Decision Letter - Yaser Mohammed Al-Worafi, Editor

PONE-D-22-19860Acceptance and hesitancy of COVID-19 vaccine among Nepalese population: a cross-sectional studyPLOS ONE

Dear Authors, 

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

==============================

Please submit your revised manuscript by 19/10/2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Yaser Mohammed Al-Worafi

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Please amend your current ethics statement to address the following concerns:

a) Did participants provide their written or verbal informed consent to participate in this study?

b) If consent was verbal, please explain i) why written consent was not obtained, ii) how you documented participant consent, and iii) whether the ethics committees/IRB approved this consent procedure.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thanks for the invitation to review this manuscript.

In the current study, Suresh Dahal et al. investigated COVID-19 vaccine hesitancy among adult Nepalese population using a cross-sectional web-based survey. The study results pointed to a low rate of COVID-19 vaccine hesitancy in the country compared to rates observed in other regions and countries worldwide.

Overall, the manuscript is well-prepared, and the study design was appropriate to reach reliable conclusions regarding the study objectives.

I have the following minor comments that hopefully can help the authors to improve the final manuscript:

Abstract: The authors can benefit from adding the cited reasons reported by the participants who were hesitant to COVID-19 vaccination.

Introduction: It was clear and provided sufficient background on the study topic and included all relevant references.

Methods: The study design was appropriate, and the methods were described in enough details to allow replication of the study. One important point that should be clarified by the authors is the exact wording of the survey item that assessed COVID-19 vaccine acceptance/hesitancy besides the possible answers. I could not access the supplementary file; therefore, I am not sure if the authors provided the complete questionnaire. If not, the authors are encouraged to do so.

Results: The study results were presented clearly including the table and figures.

Discussion and Conclusions: The study results were presented in the context of the extant literature properly and the conclusions were supported by the results. Importantly, the authors presented the potential limitations of the study.

Thanks!

Reviewer #2: This is a prevalence study, looking at vaccine hesitancy.

A few comments worth addressing.

Can the authors elaborate on the why the final questionnaire was assigned randomly to people - does this mean some did not get to complete this questionnaire? What was the random method used.

Can the authors expand on the outcome measures, was this calculated by a total /mean score from the six and seven Likert questionnaire?

Sample size was set at 200, the authors noted that, they however, collected as many responses, was this still done in the recruitment period? As it might be misleading to over collect data, more than is needed for the study.

Under the data analysis section, you may want to add, for skewed data, median (IQR) were presented.

Under data analysis, remove 95%CI, as this was not done/represented, either add 95% results or omit.

Line 210- The mean “(SD)” age of the participants was 24.15 (“6.8”).- changed to 1 d.p - be consistent throughout manuscript.

Table 1 - format so that SD is 1 d.p.

Worth mentioning in the discussion that the assumed prevalence of vaccine hesitancy used for the sample size calculator, upon collecting data in the chosen population in this study, low prevalence of vaccine hesitancy was observed.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Review comments to the authors:

Reviewer #1:

Reviewer Comments:

Thanks for the invitation to review this manuscript.

In the current study, Suresh Dahal et al. investigated COVID-19 vaccine hesitancy among adult Nepalese population using a cross-sectional web-based survey. The study results pointed to a low rate of COVID-19 vaccine hesitancy in the country compared to rates observed in other regions and countries worldwide.

Overall, the manuscript is well-prepared, and the study design was appropriate to reach reliable conclusions regarding the study objectives.

I have the following minor comments that hopefully can help the authors to improve the final manuscript:

Abstract: The authors can benefit from adding the cited reasons reported by the participants who were hesitant to COVID-19 vaccination.

Introduction: It was clear and provided sufficient background on the study topic and included all relevant references.

Methods: The study design was appropriate, and the methods were described in enough details to allow replication of the study. One important point that should be clarified by the authors is the exact wording of the survey item that assessed COVID-19 vaccine acceptance/hesitancy besides the possible answers. I could not access the supplementary file; therefore, I am not sure if the authors provided the complete questionnaire. If not, the authors are encouraged to do so.

Results: The study results were presented clearly including the table and figures.

Discussion and Conclusions: The study results were presented in the context of the extant literature properly and the conclusions were supported by the results. Importantly, the authors presented the potential limitations of the study.

Response from Author: Thank you very much for reviewing the manuscript and providing constructive feedback. The minor comment on the abstract has been addressed. (Page number 3, line number: 60-62)

A complete questionnaire (both in English and Nepali language) is submitted as a supplementary file. We hope the reviewer’s comment regarding the exact wording of the survey item that assessed COVID-19 vaccine acceptance/hesitancy besides the possible answers would be addressed via the submitted questionnaire (as a supplementary file).

Reviewer #2:

Reviewer Comments: Can the authors elaborate on the why the final questionnaire was assigned randomly to people - does this mean some did not get to complete this questionnaire? What was the random method used.

Response from Author: The questionnaire was assigned randomly to people in contact with authors via social media and instant messaging apps in various parts of the country so that responses from people of diverse ages, professions, educational qualifications, and regions could be included as a part of the study. All of the shared questionnaires were not responded to, but those who had responded were complete. However, among the respondents, very few were excluded based on exclusion criteria. (Page number 10, Line number: 213-214)

The sampling technique used was self-selected non-probability sampling.

Reviewer Comments: Can the authors expand on the outcome measures, was this calculated by a total /mean score from the six and seven Likert questionnaires?

Response from Author: The outcome measures of the study show the percentage of acceptance among the Nepalese population for vaccination against COVID-19. It also depicts the different reasons for acceptance. Similarly, it shows the percentage of hesitancy among the Nepalese population for vaccination against COVID-19 along with the different reasons for their hesitancy.

The questionnaire regarding acceptance had 6 questions and regarding hesitancy had 7 questions. All the questions were measured by a 4-unit Likert Scale including, completely agree, Agree, Disagree, and Completely Disagree. The table shows the sum of responses on each option and the percentage was calculated accordingly.

Reviewer Comments: Sample size was set at 200, the authors noted that they, however, collected as many responses, was this still done in the recruitment period? As it might be misleading to over collect data, more than is needed for the study.

Response from Author: The sample size was calculated based on the estimate of the prevalence of hesitancy toward COVID-19 vaccine among the general population in India according to Khan et al. However, we had supplied the online questionnaire to more people for assurance if some of them might be reluctant to participate and fill up the questionnaire. Also, the more response or size of the data could help us collect more diverse data and strengthen our results and conclusion. All these data were collected only during the recruitment period. After the recruitment period was completed, the online questionnaire was made unavailable.

Reviewer Comments: Under the data analysis section, you may want to add, for skewed data, median (IQR) were presented.

Under data analysis, remove 95%CI, as this was not done/represented, either add 95% results or omit.

Response from Author: Under the data analysis section, the following statement has been added. “For skewed data, median (IQR) was presented.” (Page number 9, Line number 208)

Under the data analysis section, 95% CI has been omitted.

Reviewer Comments: Line 210- The mean “(SD)” age of the participants was 24.15 (“6.8”).- changed to 1 d.p – be consistent throughout manuscript.

Table 1 - format so that SD is 1 d.p.

Response from Author: The mean “SD” age of the participants at (Page number 10, Line number: 215) along with other values in Table 1 has been corrected and made 1 d.p. so that the data are consistent throughout the manuscript.

Reviewer Comments: Worth mentioning in the discussion that the assumed prevalence of vaccine hesitancy used for the sample size calculator, upon collecting data in the chosen population in this study, low prevalence of vaccine hesitancy was observed.

Response from Author: The above author’s comment has been addressed in the discussion section. (Page number 14, Line number: 301-304)

Attachments
Attachment
Submitted filename: Response to reviewers.docx
Decision Letter - Yaser Mohammed Al-Worafi, Editor

Acceptance and hesitancy of COVID-19 vaccine among Nepalese population: a cross-sectional study

PONE-D-22-19860R1

Dear Authors, 

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yaser Mohammed Al-Worafi

Academic Editor

PLOS ONE

Formally Accepted
Acceptance Letter - Yaser Mohammed Al-Worafi, Editor

PONE-D-22-19860R1

Acceptance and hesitancy of COVID-19 vaccine among Nepalese population: a cross-sectional study

Dear Dr. Dahal:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Yaser Mohammed Al-Worafi

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .